Key result
The Montanide ISA 206B-adjuvanted SAT2 vaccine elicited comparable protection but higher neutralizing antibody and 3 times higher systemic IFN-γ responses than the Quil-A Saponin vaccine.
Why the study?
Foot-and-mouth disease vaccines providing protection against multiple serotypes for over six months with reduced cold chain reliance are urgently needed, and adjuvant efficacy depends on formulation, target species, and administration route.
Does Montanide ISA 206B adjuvant improve immune responses compared to Quil-A Saponin adjuvant in SAT2 foot-and-mouth disease vaccines in livestock?
Does Montanide ISA 206B adjuvant improve immune responses compared to Quil-A Saponin adjuvant in SAT2 foot-and-mouth disease vaccines in livestock?
Montanide ISA 206B adjuvant elicits superior neutralizing antibody and IFN-γ responses compared to Quil-A Saponin for SAT2 FMD vaccines.
Comparable protection with Montanide ISA 206B or Quil-A SAT2 vaccines in cattle; leaves open optimal thermostable formulations for extended immunity in endemic regions.
The effective control of foot-and-mouth disease (FMD) relies strongly on the separation of susceptible and infected livestock or susceptible livestock and persistently infected wildlife, vaccination, and veterinary sanitary measures. Vaccines affording protection against multiple serotypes for longer than six months and that are less reliant on the cold chain during handling are urgently needed for the effective control of FMD in endemic regions. Although much effort has been devoted to improving the immune responses elicited through the use of modern adjuvants, their efficacy is dependent on the formulation recipe, target species and administration route. Here we compared and evaluated the efficacy of two adjuvant formulations in combination with a structurally stabilized SAT2 vaccine antigen, designed to have improved thermostability, antigen shelf-life and longevity of antibody response. Protection mediated by the Montanide ISA 206B-adjuvanted or Quil-A Saponin-adjuvanted SAT2 vaccines were comparable. The Montanide ISA 206B-adjuvanted vaccine elicited a higher SAT2 neutralizing antibody response and three times higher levels of systemic IFN-γ responses at 14- and 28-days post-vaccination (dpv) were observed compared to the Quil-A Saponin-adjuvanted vaccine group. Interestingly, serum antibodies from the immunized animals reacted similarly to the parental vaccine virus and viruses containing mutations in the VP2 protein that simulate antigenic drift in nature.
No takes yet. Share an insight, caveat, or question.
Rathogwa et al. (2021) studied Foot-and-mouth disease (FMD). Montanide ISA 206B-adjuvanted SAT2 vaccine vs. Quil-A Saponin-adjuvanted SAT2 vaccine was evaluated on Protection, neutralizing antibody response, and systemic IFN-γ responses. The Montanide ISA 206B-adjuvanted SAT2 vaccine elicited comparable protection but higher neutralizing antibody and 3 times higher systemic IFN-γ responses than the Quil-A Saponin vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: